Update on Sparsentan Development in Rare Kidney Diseases

Time: 3:30 pm
day: Day Two


  • Summarizing available information from ongoing clinical trials with sparsentan in patients with IgA nephropathy and FSGS
  • Exploring data in parallel with supporting preclinical evidence
  • Navigating next steps in clinical development and beyond orphan drug designation